Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910089 · ClinicalTrials.gov registry record · Phase 4
ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,400
- Enrollment target
NCT02910089: Completed Phase 4 study, sponsored by AstraZeneca.
NCT02910089 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 1,400 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (170% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02910089, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,400 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with usual care. These engagement techniques include shared decision-making and brief negotiated interviewing and are delivered telephonically.
Primary Outcome
Pre- to post-intervention change in mean HbA1c levels
Interventions
- BEHAVIORAL Shared Decision Making
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2016-10-20 |
| Est. Completion | 2017-12-20 |
| Phase | Phase 4 |
What the finished NCT02910089 record still lists
NCT02910089 is an interventional study that assigns participants to a tested intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (170% higher).
The record links to 0 conditions, and to 1 intervention - of which Shared Decision Making is the first listed.
NCT02910089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02910089 about?
NCT02910089 is a clinical study titled "ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus". The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with usual care. These engagement techniques include shared decision-making a...
What is the current status of trial NCT02910089?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,400 participants. The study started on 2016-10-20. Estimated completion is 2017-12-20.
What interventions are being tested in trial NCT02910089?
The interventions under investigation include: Shared Decision Making (BEHAVIORAL).
Who is sponsoring clinical trial NCT02910089?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02910089's enrollment target sits among peer trials
1,400 55th of 2000 higher than 1,946 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI